Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FENNEC PHARMACEUTICALS INC.

(FENC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The Company’s only product candidate in the clinical stage of development is PEDMARK. It announced two results of Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children, including the pivotal Phase III study SIOPEL 6 and the proof-of-concept Phase III study in collaboration with the Children’s Oncology Group (COG ACCL0431). The Company’s four subsidiaries includes Oxiquant, Inc. and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc., a Canadian company, and Fennec Pharmaceuticals (EU) Limited (Fennec Limited), an Ireland company. Apart from Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

Number of employees : 9 people.
Sales per Business
20192020Delta
Pharmaceutical Products--0.23100%-
CAD in Million
Sales per region
20192020Delta
United States--0.23100%-
CAD in Million
Managers
Name Title Age Since
Rostislav C. Raykov Chief Executive Officer & Director 44 2015
Robert C. Andrade Chief Financial Officer 45 -
Chris A. Rallis Independent Director 66 2011
Khalid Islam, Dr. Chairman 64 2015
Adrian James Haigh Independent Director 60 2014
Marco Maria Brughera, Dr. Independent Director 66 2016
Shubh Goel Chief Commercial Officer 47 2019
Mark Gowland Controller - 2015
Members of the board
Name Title Age Since
Khalid Islam, Dr. Chairman 64 2015
Rostislav C. Raykov Chief Executive Officer & Director 44 2015
Chris A. Rallis Independent Director 66 2011
Adrian James Haigh Independent Director 60 2014
Marco Maria Brughera, Dr. Independent Director 66 2016
Jodi A. Cook, Dr. Director 52 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 26,006,853 21,600,785 83.1% 0 0.0% 83.1%
Shareholders
NameEquities%
Southpoint Capital Advisors LP 4,077,214 15.7%
Essetifin SpA 3,993,694 15.4%
Lawrence Kam (Investment Management) 2,495,753 9.60%
Avoro Capital Advisor LLC 1,670,000 6.42%
683 Capital Management LLC 1,110,000 4.27%
Eventide Asset Management LLC 1,040,000 4.00%
Solas Capital Management LLC 867,857 3.34%
DG Capital Management LLC 588,773 2.26%
Millennium Management LLC 404,772 1.56%
SSgA Funds Management, Inc. 327,151 1.26%
Company contact information
Fennec Pharmaceuticals, Inc.
Research Triangle Park
68 T.W. Alexander Drive
Durham, NC 27709

Phone : +1.919.636.4530
Fax : +1.919.890.0490
Web : http://www.fennecpharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Fennec Pharmaceuticals Inc.